Cytokinetics INC Form 4 insider transactions

A director at Cytokinetics Inc. sold 2,150 shares of common stock for approximately $143,620 under a pre-arranged trading plan.

Cytokinetics Director Edward M. Kaye, MD, exercised stock options and subsequently sold 28,064 shares of common stock for $66.72 per share.

CYTOKINETICS Director B. Lynne Parshall reported the sale of 5,000 shares of common stock for $64.73 per share, executed under a Rule 10b5-1 plan.

Cytokinetics EVP Fady Malik exercised stock options and immediately sold an equal number of shares under a pre-arranged plan.

Cytokinetics Inc. granted 87,297 restricted stock units to its Chief Legal & Admin Officer, Jeffrey Hessekiel, as an initial new hire grant.

A director at Cytokinetics Inc. exercised stock options and subsequently sold a portion of the acquired common stock under a Rule 10b5-1 plan.

Cytokinetics President and CEO Robert I Blum gifted 2,000 shares of common stock to two irrevocable family trusts.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, executed a pre-planned transaction, exercising stock options and selling the acquired common stock.

Cytokinetics CEO Robert I. Blum sold 5,000 shares of common stock for $62.86 per share on October 30, 2025, under a pre-arranged trading plan.

Cytokinetics Director Wendell Wierenga exercised stock options and subsequently sold an equal number of common shares under a pre-arranged trading plan.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, executed a pre-planned sale of 2,105 common shares on October 21, 2025, following the exercise of stock options.

Cytokinetics Director Wendell Wierenga acquired 99 shares of common stock at $62.80 per share as part of an equity compensation program.

Cytokinetics President and CEO Robert I. Blum sold 5,000 shares of common stock on October 16, 2025, under a Rule 10b5-1 trading plan.

Cytokinetics director Robert Arthur Harrington acquired 199 shares of common stock at $62.80 as part of an equity compensation program.

Cytokinetics Director John T. Henderson acquired 338 shares of common stock at $62.80 per share as part of an equity in lieu of cash retainer program.

Cytokinetics Director Edward M. Kaye MD acquired 199 shares of common stock at $62.80 per share as part of an equity retainer program.

Cytokinetics Director Nancy Wysenski acquired 99 shares of common stock at $62.80 per share as part of an equity in lieu of cash retainer program, increasing her total beneficial ownership to 30,873 shares.

Cytokinetics EVP of Research & Development, Fady Ibraham Malik, exercised options and sold 2,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Cytokinetics Director Edward M. Kaye MD sold 6,757 shares of common stock at $60 per share, reducing his direct beneficial ownership to 9,778 shares, pursuant to a Rule 10b5-1 plan.

Cytokinetics President & CEO Robert I Blum sold 5,000 shares of common stock at $55.05 per share under a pre-arranged trading plan.

A director at Cytokinetics Inc. has filed a Form 4 indicating a future sale of 6,695 common shares on September 30, 2025, under a Rule 10b5-1 plan.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, exercised stock options and subsequently sold an equivalent number of common shares.

Cytokinetics President & CEO Robert I. Blum sold 5,000 shares of common stock for $49.77 per share under a pre-arranged 10b5-1 trading plan.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, exercised stock options and sold an equal number of shares on September 9, 2025, under a pre-arranged 10b5-1 plan.

Cytokinetics Director Edward M. Kaye sold 6,756 shares of common stock for $50 per share on September 2, 2025, as part of a pre-arranged trading plan.

A director at Cytokinetics Inc. reported a future sale of 2,150 common shares at $48.67 per share under a pre-arranged trading plan.

Cytokinetics President and CEO, Robert I. Blum, sold 5,000 shares of common stock for $48.76 per share under a pre-arranged 10b5-1 trading plan.

Cytokinetics Director James M. Daly was granted 27,450 non-qualified stock options with an exercise price of $37.84, effective August 19, 2025.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, sold 2,000 shares of common stock for $38.31 per share after exercising stock options at $10.60 per share.

Cytokinetics CEO Robert I. Blum sold 5,000 shares of common stock for $38.42 per share in a pre-planned transaction.